ClinicalTrials.gg
CompletedNCT03351933GamaSTANUpdated Jul 30, 2019Results posted

Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)

A Phase 4 interventional study of Immune Globulin (Human) in Anti-Hepatitis A Antibody Levels in Heathy Subjects, sponsored by Grifols Therapeutics LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-30.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 144 studies in Hepatitis with a site in United States — 13 open to participants now, 17 under way, 2 of them phase 3. Hepatitis · United States.

Enrollment
89th of 117
28 · median 67
Started
2017
with 2 others
Phase 4
8 of 144
none open now
Registered
109th of 144
by date

Among the 144 studies in Hepatitis with a site in United States, this one is the 89th largest by enrollment of the 117 interventional ones that give a count, is one of 3 that started in 2017, is one of 8 in phase 4, and was the 109th registered.

Hepatitis

343 studies on the registry are indexed under Hepatitis; 52 are open to participants now.

Browse Hepatitis studies →

Open to participants now

13 of the 144 studies in Hepatitis with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hepatitis studies recruiting now, 23 (64%) set no upper age limit and 11 (31%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Hepatitis with a site in United States, or all of them as a file.
02

Study summary

This was a single center, open-label, single-arm study in which approximately 28 Hepatitis A virus (HAV)-seronegative healthy subjects were enrolled. There was a screening period of up to 28 days during which subjects were screened for enrollment in the study.

Healthy subjects received a single intramuscular (IM) dose of GamaSTAN (0.2 mL/kg), followed by a pharmacokinetic (PK) sampling period of 150 days (approximately 5 half-lives). The protective levels of anti-HAV antibodies were assessed up to 60 days after the administration of GamaSTAN. A PK curve was obtained during the PK sampling period.

Read the detailed description

This was a single center, open-label, single-arm study design, in which approximately 28 subjects received the same study treatment (0.2 mL/kg dose via IM injection). There was no reference therapy in this study.

The study was explained to each subject prior to the subject providing written informed consent. All subjects were screened to ensure that all the inclusion criteria and none of the exclusion criteria were met.

A sufficient number of healthy male and female subjects were qualified by screening assessments and procedures for reporting to the clinical site on Day -1. The healthy subjects received a single IM dose of GamaSTAN (0.2 mL/kg) on Day 1. Subjects were discharged from the clinic on Day 2, following the scheduled assessments and procedures, and returned to the clinical site for the remaining ambulatory PK samples and safety monitoring, and again for the final visit (Day 150).

The total duration of study participation for subjects who completed the study were approximately 178 days.

03

Conditions studied

  • Anti-Hepatitis A Antibody Levels in Heathy Subjects

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male subjects from 18 to 55 years of age, inclusive, or female subjects from 18 to 65 years of age, inclusive
  2. Subjects with a (BMI) of 18.5 to 29.9 kg/m2
  3. Body weight greater than or equal to 50 kg at screening
  4. Subjects willing and able to provide written
  5. Subjects in good health in the judgment of the Investigator, as determined by medical history, physical examination, vital signs, and laboratory assessments
  6. A female study subject must meet one of the following criteria:

    1. If a female of - agrees to use one of the accepted regimens from at least 30 days prior to study treatment administration and during the entire study duration. An acceptable method of contraception includes one of the following:

      • Abstinence from heterosexual intercourse (i.e. when abstinence is the preferred and usual lifestyle of the subject; periodic abstinence is not acceptable)
      • Non-estrogen containing hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal birth control products, transdermal patch)
      • Intrauterine device without hormones
      • Condom with spermicide
      • Diaphragm or cervical cap with spermicide
      • Vasectomized partner (minimum 6 months since vasectomy prior to study treatment administration)
    2. If a female of non-childbearing potential - should be surgically sterile (i.e. has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or in a menopausal state (at least 1 year without menses prior to study treatment administration)
  7. A male study subject must agree to use one of the accepted contraceptive regimens during the entire study duration;

    • Abstinence from heterosexual intercourse
    • Female partner with condom with spermicide used by male study subject
    • Female partner of non-childbearing potential
    • Male sterilization (if proof of sterilization is not provided, the subject must agree to use one of the above accepted contraceptive methods)
  8. A male study subject must agree not to impregnate a female or donate sperm during the entire study duration

Exclusion criteria

Exclusion Criteria:

  1. Subject vaccinated against HAV, as documented the in medical history at the screening visit
  2. Subject with positive anti-HAV antibodies in blood sample at the screening visit
  3. Subject who previously received any type of IG, including HAV IG within the past 12 months prior to study treatment administration
  4. Subject with prolonged (INR) or activated partial thromboplastin time (aPTT) at the screening visit
  5. Subject with a count below 100×109/L at the screening visit
  6. Subject suffering from some acute or chronic medical, surgical or psychiatric significant condition or laboratory abnormality at the screening visit or prior to study treatment administration that, according to Investigator judgement, may increase the risk associated with study participation or study treatment administration, or may interfere with the successful completion or interpretation of the study results
  7. Subject with a history of the following: angioedema, cardiac arrhythmia, angina pectoris, myocardial infarction, cerebrovascular accident, cardiac failure, thrombotic events, embolism, coagulopathy, diabetes mellitus, hyperlipidaemia, nephrotic syndrome, acute renal injury, , asthma, hepatic disease, reticuloendothelial system dysfunction, or nervous system disorder
  8. Subject with known personal or family history of abnormal bleeding episodes
  9. Subject not willing to receive study treatment via IM route of administration or unable to receive study treatment via IM route of administration
  10. Subject with cardiovascular risk factors based on medical history: active tobacco smoking and/or ongoing diabetes mellitus at the screening visit
  11. Subject with thrombosis risk factors: prolonged immobilization within 2 months prior to the screening visit, history of venous or arterial thrombosis, use of estrogens (30 days prior to the study drug administration), indwelling central vascular catheters and hyperviscosity or hypercoagulable states
  12. Subject with known history of /allergic reaction to blood/plasma products
  13. Subject with known selective IgA deficiency (with or without antibodies to IgA)
  14. Subject who received any plasma-derived product infusion within 12 months prior to study treatment administration
  15. Subject who received a blood or plasma transfusion within 12 months prior to study treatment administration
  16. Subject with systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg at the screening visit and prior to treatment administration
  17. Subject with anemia ( \<12 g/dL in women and 13 g/dL in men) at the screening visit
  18. Subjects with proteinuria (>1+ on urine dipstick), blood urea nitrogen (BUN) or creatinine greater than the at the screening visit
  19. Subject with liver enzymes ( [AST], alanine aminotransferase [ALT] and gamma-glutamyl transferase [GGT]) levels greater than the upper limit of normal at screening visit
  20. Subject who received any dose of parenteral, oral, or inhaled , , or immunomodulators within 6 weeks prior to the screening visit
  21. Subject who received any within five months prior to the screening visit
  22. Subject not willing to postpone receiving any live virus vaccines until 6 months after receiving IP
  23. Currently receiving any anti-viral treatment, regardless of the route of administration
  24. Subject with virus safety laboratory results (serology and/or nucleic acid amplification technology [NAT]) indicative of a current infection with hepatitis A virus (HAV), virus (HBV), virus (HCV), (HIV) or parvovirus B19 (B19V) at the screening visit
  25. Participated in another clinical trial within 30 days prior to the screening visit or has received any IPs within 3 months prior to the screening visit
  26. Positive urine drug panel testing at the screening visit or prior to study treatment administration
  27. Known or suspected abuse of alcohol, opiates, psychotropic agents or other drugs or chemical substances; or has done so in the 12 months prior to the screening visit
  28. In the opinion of the Investigator, the subject may have compliance problems with the protocol and the procedures of the protocol
  29. Subject who has already been included in a previous group for this clinical study
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Immune Globulin (Human) GamaSTAN

    The healthy subjects received a single IM dose of GamaSTAN (0.2 mL/kg), followed by a PK sampling period of 150 days.

    Biological: Immune Globulin (Human)

Interventions

  • A single 0.2 mL/kg IM injection of Immune Globulin (Human) (GamaSTAN) was administered in healthy subjects.

    Also known as: GamaSTAN

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Maintaining Protective Anti- HAV Antibody Levels

    Percentage of subjects maintaining anti-HAV antibody levels ≥10 mIU/mL up to Day 60 following study treatment administration.

    Time frame: Day 60

07

Results

Posted Jul 30, 2019

Participant flow

Participant flow — Overall Study
MilestoneImmune Globulin (Human) GamaSTAN
Started28
Completed26
Not completed2

Outcome measures

PrimaryPercentage of Subjects Maintaining Protective Anti- HAV Antibody Levels

Percentage of subjects maintaining anti-HAV antibody levels ≥10 mIU/mL up to Day 60 following study treatment administration.

Time frame:
Day 60
Reported as:
Count of participants · Participants
Percentage of Subjects Maintaining Protective Anti- HAV Antibody Levels
ParticipantsImmune Globulin (Human) GamaSTAN
Percentage of Subjects Maintaining Protective Anti- HAV Antibody Levels26

Adverse events

Collected over Adverse events occurring at any time between signing of the subject's ICF and the last day of the subject's participation in the clinical trial were reported. The total time period for the adverse event data collection was 178 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Immune Globulin (Human) GamaSTAN0/28 (0%)0/28 (0%)28/28 (100%)
Most frequent other events
Most frequent other events
EventImmune Globulin (Human) GamaSTAN
Injection site painGeneral disorders20/28
HeadacheNervous system disorders5/28
Vascular access site haemorrhageInjury, poisoning and procedural complications2/28
Neutrophil count decreasedInvestigations2/28
White blood cell count decreasedInvestigations2/28
Nasal congestionRespiratory, thoracic and mediastinal disorders2/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)Immune Globulin (Human) GamaSTAN
Mean41 (22 to 61)
Sex: Female, Male
Sex: Female, Male(Participants)Immune Globulin (Human) GamaSTAN
Female15
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Immune Globulin (Human) GamaSTAN
Hispanic or Latino3
Not Hispanic or Latino25
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Immune Globulin (Human) GamaSTAN
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American9
White18
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Vince & Associates Clinical Research, Inc.
    Overland Park, Kansas 66212, United States
09

References and documents

Publications

  • Kankam M, Griffin R, Price J, Michaud J, Liang W, Llorens MB, Sanz A, Vince B, Vilardell D. Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects. Adv Ther. 2020 May;37(5):2373-2389. doi: 10.1007/s12325-020-01327-9. Epub 2020 Apr 16. PubMed 32301062 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Apr 2018, 5 months.

Results were first posted in Jul 2019, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2017
First posted
Nov 24, 2017
StartActual
Oct 31, 2017
Primary completionActual
Apr 27, 2018
CompletionActual
Jul 19, 2018
Results first posted
Jul 30, 2019
Last update
Jul 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03351933
Responsible party
Sponsor
First posted
Nov 24, 2017
Start date
Oct 31, 2017
Primary completion
Apr 27, 2018
Completion
Jul 19, 2018
Results posted
Jul 30, 2019
Last update
Jul 30, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion